SYNDIVIA
- Biotech or pharma, therapeutic R&D
Syndivia specializes in utilizing its proprietary and unique GeminiMab™ technology — the first and only hinge-region Cys229 site-specific ADC technology applicable to native mAb — to generate ADCs with improved TI.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}